Trane Technologies to Acquire Farrar Scientific, a Leader in Ultra-Low Temperature Control for Biopharmaceutical and other Life Science Industries

Rhea-AI Summary

Trane Technologies (NYSE: TT) has announced its acquisition of Farrar Scientific, a leader in ultra-low temperature control, for an upfront value of $250 million, potentially rising to $365 million based on future performance. This acquisition is set to enhance Trane's capabilities in the biopharmaceutical sector, addressing the escalating demand for ultra-low temperature processes in the healthcare industry. Holly Paeper has been appointed president of the new Life Science Solutions business, aiming to expand operations globally.

Positive

• Acquisition expands capabilities in ultra-low temperature control, enhancing access to biopharma markets.
• Addresses fast-growing demands for ultra-low temperature processes in drug and vaccine manufacturing.
• Expected to be modestly accretive to EPS in the first three years.

Negative

• Total transaction value may lead to financial strain with an upfront payment and additional payout potential.
• Integration challenges may arise from merging operations with a newly acquired entity.

• Acquisition expands the company’s capabilities in ultra-low temperature control; increases access to biopharma and other life science markets at highly accretive EBITDA margins
• Helps meet fast-growing demands for ultra-low temperature processes in manufacturing and storage of medicines, vaccines and other life science products
• Holly Paeper appointed president of Trane Technologies’ new Life Science Solutions business, which will grow and scale the early-stage business globally

SWORDS, Ireland--(BUSINESS WIRE)-- Trane Technologies (NYSE: TT), a global climate innovator, announced that it has signed an agreement to acquire Farrar Scientific, a leader in ultra-low temperature control for biopharmaceutical and other life science applications.

Farrar Scientific’s proprietary technology fills an unmet need for flexible, modular, and efficient ultra-low temperature process and storage, including cooling and heating/thawing. The solutions can provide an alternative to large-scale freezer farms or capital-intensive cold rooms used in manufacturing of drugs, vaccines and other biological products.

“Farrar Scientific has revolutionized ultra-low temperature control for biopharmaceutical companies and become a critical supplier to large pharma customers,” said Dave Regnery, CEO of Trane Technologies. “It brings technologies that meet critical needs in the addressable healthcare manufacturing and bioprocessing market, which is expected to grow to $1.65 billion by 2023.

“Leveraging our expertise in sustainable climate controls, our global footprint, and best-in-class business operating system, Trane Technologies will profitably grow and scale the pioneering solutions from this early-stage company. We also look forward to expanding our role in helping to provide vaccines, medicines and other healthcare products that are important to quality of life around the world.”

Trane Technologies will acquire 100% of Farrar Scientific’s assets, including its patented ultra-low temperature control technologies, a development and assembly operation in Marietta, Ohio, and a specialized team of engineers, sales engineers, operators, and technicians.

Holly Paeper, current vice president of Strategic Sales, Commercial HVAC Americas, has been appointed president of the new business, Trane Technologies Life Science Solutions, which will operate as part of the company’s Commercial HVAC Americas business unit.

Paeper is consistently recognized for her ability to nurture innovation and big ideas, build and scale high-growth businesses and cultivate high-performance teams. Paeper’s prior roles include vice president of marketing and general manager of data centers for Trane; and executive leadership roles in product management, marketing, sales, strategy and M&A for Corning, Eaton Corporation and Intel Corporation.

Farrar Scientific personnel will join the Trane Technologies’ Life Science Solutions team. This includes Scott Farrar, founder and chief technology officer of Farrar Scientific, who will serve as vice president of technology and innovation. Jim Vuksic, Farrar Scientific’s president and CEO, will serve as an advisor to the team.

The upfront transaction value is $250 million, with a total transaction value of up to $365 million inclusive of $115 million in additional payout potential in 2025 tied to the attainment of key financial targets. The acquisition will be funded with available cash on hand, and is expected to be modestly accretive to EPS in the first three years. Additional details of the transaction were not disclosed and are not material. The transaction is expected to close in the fourth quarter of 2021, subject to regulatory approval and customary closing conditions.

About Trane Technologies

Trane Technologies is a global climate innovator. Through our strategic brands Trane and Thermo King, and our environmentally responsible portfolio of products and services, we bring efficient and sustainable climate solutions to buildings, homes, and transportation. Learn more at tranetechologies.com.

This news release includes “forward-looking statements,” which are statements that are not historical facts, including statements about the proposed transaction and the anticipated timing thereof; the expected benefits of the proposed transaction, the projected growth of the healthcare manufacturing market, the impact of the transaction on our financial positions, results of operations, cash flows, financing plans, business strategy, operating plans, capital and other expenditures and competitive positions. These forward-looking statements are based on our current expectations and are subject to risks and uncertainties, which may cause actual results to differ materially from our current expectations. Such factors include, but are not limited to, our ability to timely obtain necessary regulatory approvals of the proposed transaction and to timely complete the proposed transaction; our ability to fully realize the expected benefits of the proposed transaction; negative effects of announcement or consummation of the proposed transaction on the market price of the company’s ordinary shares; significant transaction costs and/or unknown liabilities; general economic and business conditions that may impact the companies in connection with the proposed transaction; the impact of the proposed transaction on the company’s employees, customers and suppliers; and the ability of the companies to successfully integrate operations after the transaction. Additional factors that could cause such differences can be found in our Form 10-K for the year ended December 31, 2020, as well as our subsequent reports on Form 10-Q and other SEC filings. We assume no obligation to update these forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210913005204/en/

Media Contact:

Jennifer Regina

+1-630-390-8011

Jennifer.regina@tranetechnologies.com



Investors Contact:

Zachary Nagle

+1-704-990-3913

zachary.nagle@tranetechnologies.com

Source: Trane Technologies

FAQ

What is the purpose of Trane Technologies' acquisition of Farrar Scientific?

The acquisition aims to enhance Trane's capabilities in ultra-low temperature control for biopharmaceutical applications.

What is the total value of the acquisition deal between Trane Technologies and Farrar Scientific?

The upfront transaction value is $250 million, with potential total value up to $365 million.

When is the acquisition of Farrar Scientific expected to close?

The acquisition is expected to close in the fourth quarter of 2021, pending regulatory approval.

Who has been appointed to lead Trane Technologies' new Life Science Solutions business?

Holly Paeper has been appointed as president of the new Life Science Solutions business.

How will the acquisition impact Trane Technologies' financial performance?

The acquisition is expected to be modestly accretive to earnings per share within the first three years.